Anne-sofie Schrohl

Copenhagen, 2100, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.

Journal: BMC genomics

Published: October 20, 2015

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.

Journal: BMC cancer

Published: July 21, 2015

Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.

Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: July 09, 2014

TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.

TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.

Journal: Journal of proteome research

Published: August 06, 2013

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: April 23, 2013

Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.

Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.

Journal: BMC cancer

Published: December 20, 2012

TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.

TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: November 05, 2012

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies.

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies.

Journal: Histopathology

Published: November 19, 2011

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.

Journal: BMC cancer

Published: April 28, 2009

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: March 17, 2008

Showing 1-10 of 10

Last Updated: 09/26/2026